App-Quantinova.ai

Monitoring pharmacodynamic response to nucleoside analogs targeting DNMT1 using p16/INK4a re-expression in circulating tumor cells.

Robert J. Kinders - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

N/A

Dynamic monitoring and predictive value of circulating tumor cells in EGFR mutant advanced NSCLC patients treated with first-line EGFR-TKIs.

ChunXia Su - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Association between ERCC1 polymorphisms and nephrotoxicity in non-small cell lung cancer patients undergoing platinum-based chemotherapy.

Corine de Jong - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Carboplatin

Improvement of NGS uniformity of single cell sequencing in CTCs by WGA QC and increased sequencing throughput.

Lin Ze Shiang - American Society of Clinical Oncology (ASCO) , 2018

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Phase II study of maintenance pembrolizumab (pembro) in extensive stage small cell lung cancer (ES-SCLC) patients (pts).

Shirish M. Gadgeel - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pembrolizumab

Circulating tumor cell (CTC) number as a response endpoint in metastatic castration resistant (mCRPC) compared with PSA across five randomized phase 3 trials.

Glenn Heller - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Clinical outcome of metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with a post-treatment circulating tumor cell (CTC) of 0 vs CTC > 0: Post hoc analysis of COU-AA-301.

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Association of androgen receptor (AR) gene status in plasma DNA with outcome on enzalutamide in chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC): Exploratory results from the PREMIERE trialOn behalf of SOGUG.

Enrique Grande - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Whole blood androgen receptor (AR) variant (ARV12, ARV14) expression and overall survival (OS) in metastatic castrate resistant prostate cancer (mCRPC).

Karthik Giridhar - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Association of CTC detection by AdnaTest with outcome on enzalutamide in chemotherapy-naive castration-resistant prostate cancer: Exploratory results from PREMIEREA SOGUG trial.

Albert Font Pous - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

A randomized phase II study of pelareorep (REO) plus docetaxel vs. docetaxel alone in patients with metastatic castration resistant prostate cancer (mCRPC): Canadian Cancer Trials Group study IND 209.

Bernhard J. Eigl - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Pelareorep

Trop-2 expression on treatment resistant cancer cells in castrate-resistant prostate cancer (CRPC) as a predictive biomarker for targeted therapy.

Kimberly Peihsi Ku - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Indentification of a CTC-based gene expression signature predicting resistance to abiraterone and enzalutamide in mCRPC.

Todd Matthew Morgan - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Changes in CTC burden and prevalence of specific CTC subtypes in mCRPC patients (pts) receiving alpharadin (Ra-223) as single agent or in combination with other therapuetics (Tx).

Ryan Vance Dittamore - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Alpharadin

Circulating tumor cell subsets and macrophage polarization to predict efficacy of cabozantinib in advanced prostate cancer with visceral metastases.

Edwin M. Posadas - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Cabozantinib

Circulating tumor cells (CTCs) N-terminal androgen receptor expression to identify patients (pts) with castrate resistant prostate cancer (CRPC) who are more sensitive to chemotherapy.

Susan F. Slovin - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

CB-7598

Baseline CTC subtype to predict outcomes on mCRPC patients (pts) receiving enzalutamide (E) compared to abiraterone (A).

Howard I. Scher - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Circulating tumour cells and survival in abiraterone- and enzalutamide-treated patients with castration-resistant prostate cancer.

Bram De Laere - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Enzalutamide

Phase 2 biomarker-driven study of ipilimumab plus nivolumab (Ipi/Nivo) for ARV7-positive metastatic castrate-resistant prostate cancer (mCRPC).

Karim Boudadi - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Ipilimumab

Phase I dose-escalation study of fractionated-dose 177Lu-PSMA-617 for progressive metastatic castration resistant prostate cancer (mCRPC).

Scott T. Tagawa - American Society of Clinical Oncology (ASCO) , 2017

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

N/A

Docetaxel

Filters

1671 Abstracts